Aspire Biopharma (ASBP) announced the appointment of Phillip Balatsos to its Board of Directors, effective February 6. The appointment follows the planned departures of Suren Ajjarapu and Donald Fell, from the board. Phillip Balatsos is a senior financial markets executive and board director with over 25 years of experience across foreign exchange, emerging markets, institutional sales and trading, and public company governance. He has held leadership roles at global financial institutions including Barclays Capital, Credit Suisse, and XP Investments, and currently operates within an independent trading platform at Oscar Gruss & Son. Phillip Balatsos will serve on the Audit and Compensation Committees.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASBP:
- Aspire Biopharma Announces Private Placement to Strengthen Finances
- Aspire Biopharma files patent application for sublingual ondansetron formulation
- Aspire Biopharma regains compliance with Nasdaq minimum bid price rule
- Aspire Biopharma’s Buzz Bomb partners with Blue Shark Beverages
- Aspire Biopharma Raises $2 Million Through Private Financing